Clinical trials: Primary Cancer of the Peritoneum
Melanoma, Non-small Cell Lung Cancer
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer
- Trial name
- NCT03329950
- Testing
- CDX-1140, CDX-301, pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 132 people
- Sponsor
- Celldex Therapeutics
Ovarian Carcinoma, Peritoneal Carcinoma
Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer
The purposes of this study are to determine: 1) if treatment with interferon gamma-1b plus standard chemotherapy (carboplatin and paclitaxel) can increase the overall survival of patients with advanced ovarian or primary…
- Trial name
- NCT00047632
- Testing
- Interferon gamma-1b
- Where
- United States
- Volunteers
- 847 people
- Sponsor
- InterMune
Ovarian Cancer, Fallopian Tube Cancer
A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy
This is a Phase 1b/2a multicenter study, which consists of two parts: Part 1: the Phase 1b part of the study will investigate the safety of the combination of ATX-101 with carboplatin/pegylated liposomal doxorubicin (ACD).
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, High Grade Serious or Endometrioid Carcinoma of the Ovary, Fallopian Tube, or Primary Peritoneal Cancer
- Trial name
- NCT04814875
- Testing
- ATX-101 + Carboplatin + Pegylated liposomal doxorubicin (ACD)
- Where
- 6 sites in Australia
- Volunteers
- 16 people
- Sponsor
- THERAPIM PTY LTD
Ovarian Cancer, Peritoneal Neoplasms
A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer
To evaluate the efficacy of voloxicimab when administered at 15 mg/kg qwk in subjects with platinum-resistant, advanced epithelial ovarian cancer or primary peritoneal cancer.
- Trial name
- NCT00516841
- Testing
- Volociximab
- Where
- 23 sites in United States, Canada
- Volunteers
- 16 people
- Sponsor
- Facet Biotech
Fallopian Tube Cancer, Ovarian Cancer
A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This is a Phase I, multicenter, open-label, dose-escalation study of single-agent D4064A administered by IV infusion to patients with recurrent or persistent epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), and…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- Trial name
- NCT00753480
- Testing
- D4064A
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Genentech, Inc.
Ovarian Neoplasms, Primary Peritoneal Cancer
Study of Pemetrexed in the Treatment of Patients With Ovarian Cancer Who Have Failed Prior Platinum-Based Chemotherapy
The purposes of this study are to determine: - whether standard or higher doses of pemetrexed should be given to patients with ovarian or primary peritoneal cancer that has recurred; - the safety and side effects of standard and…
- Trial name
- NCT00109096
- Testing
- Pemetrexed
- Where
- 21 sites in Belgium, Germany and 2 more
- Volunteers
- 100 people
- Sponsor
- Eli Lilly and Company
Fallopian Tube Cancer, Primary Peritoneal Cancer
A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)
The primary purpose of the study is to evaluate the efficacy of R-DXd with or without bevacizumab as maintenance therapy compared with standard of care (SOC) in participants with platinum-sensitive ovarian cancer (PSOC) as…
- Conditions
- Fallopian Tube Cancer, Primary Peritoneal Cancer, High-Grade Serous Ovarian Cancer, Endometrioid Epithelial Ovarian
- Trial name
- NCT07791732
- Testing
- R-DXd, Bevacizumab
- Volunteers
- 600 people
- Sponsor
- Daiichi Sankyo
Ovarian Cancer
A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma
The purpose of this study is to determine the overall response rate, time to progression, and 1 yr survival with cetuximab in patients with ovarian or primary peritoneal carcinoma.
- Trial name
- NCT00082212
- Testing
- Cetuximab
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- Eli Lilly and Company
Ovarian Cancer
A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer
Niraparib is a PARP inhibitor. This is a 2:1 randomized, double-blind, placebo-controlled study conducted in patients with advanced (FIGO Stage III or IV) ovarian cancer to evaluate Efficacy and Safety of ZL-2306 (Niraparib) for…
- Trial name
- NCT03709316
- Testing
- ZL-2306 (Nirapairb)
- Where
- 31 sites in China
- Volunteers
- 384 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status
This is a non-randomized, open-label study to assess olaparib tablets as a treatment for subjects with different homologous recombination deficiency (HRD) tumor status and with platinum-sensitive, relapsed, high-grade serous or…
- Trial name
- NCT02983799
- Testing
- OLAPARIB
- Where
- 47 sites in United States, Canada
- Volunteers
- 272 people
- Sponsor
- AstraZeneca
Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
The main purpose of this study is to: Learn about the safety of ubamatamab and to find out what dose of ubamatamab can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus The study will also…
- Conditions
- Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer
- Trial name
- NCT03564340
- Testing
- Ubamatamab, Cemiplimab, Sarilumab
- Where
- 54 sites in United States, Australia and 8 more
- Volunteers
- 890 people
- Sponsor
- Regeneron Pharmaceuticals
Ovarian Carcinoma, Fallopian Tube Cancer
A Trial Evaluating TG4050 in Ovarian Carcinoma.
This is a multicenter, open-label, single arm phase I study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with ovarian, fallopian or peritoneal serous carcinoma.
- Conditions
- Ovarian Carcinoma, Fallopian Tube Cancer, Peritoneal Carcinoma
- Trial name
- NCT03839524
- Testing
- TG4050
- Where
- 6 sites in United States, France
- Volunteers
- 64 people
- Sponsor
- Transgene
Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety and tolerability of IMGN151 when given as monotherapy and in combination with other…
- Conditions
- Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer (PSOC)
- Trial name
- NCT07024784
- Testing
- IMGN151, Carboplatin, Bevacizumab
- Where
- 21 sites in United States, Israel and 1 more
- Volunteers
- 377 people
- Sponsor
- AbbVie
Ovarian Neoplasms, Peritoneal Neoplasms
BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer
This phase I, open label dose escalation study will investigate the addition of BIBF 1120 to treatment with the combination of carboplatin and Pegylated Liposomal Doxorubicin (PLD) in patients with advanced, platinum sensitive…
- Trial name
- NCT01314105
- Testing
- BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min, BIBF 1120+ PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
- Where
- 3 sites in Spain
- Volunteers
- 19 people
- Sponsor
- Boehringer Ingelheim
Epithelial Ovarian Cancer, Fallopian Tube Cancer
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
The purpose of this study is to compare the overall survival of patients treated with VTX-2337 + pegylated liposomal doxorubicin (PLD) versus those treated with PLD alone in women with recurrent or persistent, epithelial ovarian…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT01666444
- Testing
- pegylated liposomal doxorubicin (PLD), VTX-2337
- Where
- 136 sites in United States
- Volunteers
- 297 people
- Sponsor
- Celgene
Epithelial Ovarian Cancer, Fallopian Tube Cancer
A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)
This trial is a registered, phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with platinum-resistant recurrent epithelial ovarian cancer.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT06994195
- Testing
- BL-B01D1, Liposomal doxorubicin, Paclitaxel or Topotecan
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Fallopian Tube Cancer, Ovarian Cancer
TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer
The purpose of this study is to determine if treatment with paclitaxel plus AMG 386 is superior to paclitaxel plus placebo in women with recurrent partially platinum sensitive or resistant epithelial ovarian cancer, primary…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT01204749
- Testing
- AMG 386, Paclitaxel
- Where
- 225 sites in United States, Australia and 30 more
- Volunteers
- 919 people
- Sponsor
- Amgen
Ovarian Cancer, Fallopian Tube Cancer
A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy
This is a multicenter, randomized, blinded, 3-arm Phase 3 study to evaluate the efficacy and safety of Fluzoparib alone or with Apatinib versus Placebo, as maintenance treatment, in patients with Stage III or IV ovarian cancer.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT04229615
- Testing
- Fluzoparib; Apatinib, Fluzoparib
- Where
- China
- Volunteers
- 690 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Fallopian Tube Cancer, Ovarian Cancer
Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating patients who have recurrent…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00004060
- Testing
- exatecan mesylate
- Where
- United States
- Sponsor
- Daiichi Sankyo
Primary Peritoneal Cancer, Fallopian Tube Cancer
RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of RC88 monotherapy in subjects with Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer.
- Conditions
- Primary Peritoneal Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer
- Trial name
- NCT06173037
- Testing
- RC88
- Where
- 30 sites in China
- Volunteers
- 43 people
- Sponsor
- RemeGen Co., Ltd.